Browsing by Author "Giwa A., Giwa H. B., Jamiu M.O."
Now showing 1 - 2 of 2
Results Per Page
Sort Options
Item Cost Effectiveness Analysis of Combined Anti-Retroviral Therapy in a Tertiary Health Institution(West African Journal of Pharmacy, 2018-03) Giwa A., Giwa H. B., Jamiu M.O.Background: The increasing health care spending from government, donors and private stand-point has a lot of challenge in health care related decision making. Hence, there is need to examine closely the cost and benefits of drug interventions especially in chronic illnesses like HIV/AIDS. Objective: To conduct cost-effectiveness analysis of combined antiretroviral therapy (cART) in a tertiary health institution Methods: A retrospective review of systematically sampled 360 case notes was conducted. World Health Organization Defined Daily Dose method of evaluating drug use and probability method for potential effectiveness of cART options from literature analysis was employed in determining cost-effectiveness of each option identified from cART drug utilization studies. Results: Zidovudine (AZT )+Lamivudine (3TC) +Nevirapine (NVP)which cost N89 2 ($ 0.3 per unit effectiveness) was more frequently prescribed (86%, =100.82; P=0.00; df=1). This combination was more cost effective than the less frequently prescribed first line option of Tenofovir (TDF) +Lamivudine (3TC) +Efavirenz (EFV)at a cost per unit effectiveness of NGN 134 ($0.45).Similarly, 2 AZT+3TC+Lopinavir/Ritonavir (LPV/r)which was more frequently prescribed (71.4%, =33.62; P=0.00; df=1)]with cost per unit effectiveness of NGN379 ($1.26)was more cost effective than TDF+3TC+LPV/r [NGN403($ 1.34) per unit of effectiveness] in the management of HIV/AIDS patients as second line regimen. Conclusions: AZT+3TC+NVPwas more cost-effective than TDF+3TC+EFV in the management of HIV/AIDS patients as firstline regimen. However, AZT+3TC+LPV/r appeared to, but was not necessarily more cost effective than TDF+3TC+LPV/r in the management of HIV/AIDS patients as second line regimenItem Cost of Illness Analysis of Human Immuno- Deficiency Virus/Acquired Immuno-Deficiency Syndrome (HIV/AIDS) in a Developing Economy(West African Journal of Pharmacy., 2018-09) Giwa A., Giwa H. B., Jamiu M.O.Background: Highly Active Antiretroviral Therapy is for lifetime of the patients from time of diagnosis of HIV/AIDS. This translates into a substantial cost in drug therapy to the patients, government and donor agencies. Objective: To conduct cost of illness analysis of HIV/AIDS in a Developing Economy in 2016. Methods: A one-year retrospective review of 2560 prescriptions of 396 HIV/AIDS patients' case notes from January to December, 2016 obtained by systematic random sampling from 4800 case-notes of subjects that participated in this study was conducted. Sampling Interval =10 A data collection form was designed and used to collect data generated from the selected case notes. Cost of Illness was determined by prevalence rate method, using direct costs only. Results: The annual cost of illness for the 396 HIV/AIDS patients on highly active antiretroviral therapy was ?40,674,760 (US$127,108.3) with drug, diagnostic/monitoring tests, transport, care/support and personnel cost components of ?25,479,760; US$79,624.3 (62.64%), ?7,200,000; US$22,500 (17.71%), ?1,440,000; US$4,500(3.54%), ?2,880,000; US$9,000 (7.08%) and ?3,675,000; US$11484 (9.03%) respectively. The annual average cost of illness of HIV/AIDS was ?102,714.04 (US$320.98) Conclusion: The annual average cost of illness of HIV/AIDS represent 97% of annual per capita income. This is enormous. The Annual National cost of illness for HIV/AIDS in Nigeria, a developing economy may be about N590 billion annually.